$226M in cash, cash equivalents, restricted cash and short-term investments as of June 30, 2025, expected to fund operations for over two years before accounting for anticipated ZEVASKYN revenue beginning in 3Q 2025 and projected profitability in 1H 2026
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics announces employee inducement grants
- AscellaHealth highlights value of HUB partnership with Abeona Therapeutics
- Abeona Therapeutics Amends Loan Agreement with Avenue
- Abeona Therapeutics’ Gene Therapy Trial for MPS IIIA: A Promising Update
- Abeona announces ZEVASKYN available at new Qualified Treatment Center